INVENTURUS KNOWLEDGE SO L (IKS) Fair Value & Analysis
Healthcare · IN · Market cap ₹308B (≈ $3.3B) · ISIN INE115Q01022
What is INVENTURUS KNOWLEDGE SO L really worth?
A solid business, but trading 87% above our fair value of ₹941.50.
Strengths
Risks
Fair value as of: Aug 23, 2026
From 26 valuation models · updated 13 days ago
Share price −6.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 71/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (₹588.51 to ₹1,758). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (21 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.
How to read this chart
21‑month range ₹1,275 – ₹2,146 · fair‑value band ₹588.51 – ₹1,758 · the ₹1,760 price screens above the ₹941.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 23, 2026.
Analysis
INVENTURUS KNOWLEDGE SO L (IKS) currently trades at ₹1,760, while our model-based Fair Value estimate is ₹941.50, implying the stock looks roughly 86.9% overvalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹2,174 per share, and 6 of the 26 models we run sit above the ₹1,760 price. Bear case: the Asset-Based group reads lowest at ₹111.84, and 20 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, INVENTURUS KNOWLEDGE SO L generated revenue of ₹31.9B at a net margin of 22.6%. Revenue grew 18.5% year over year. It earns a return on equity of 31.4%. Net debt stands at ₹3.6B. Fundamentals as of Aug 23, 2026
Our scenario range runs from ₹588.51 (bear case) to ₹1,758 (bull case); at ₹1,760, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 39% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −68% fair-value upside, at −47%, IKS screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹18.19 per share, which is 1.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth Earnings (₹2,174) versus Asset-Based (₹111.84). Highest evidence: EPV (74).
Notify me when IKS reaches fair value
Put IKS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform that assists physician businesses in outpatient and inpatient care activities in the United States, Canada, and Australia.
Full company description
Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform that assists physician businesses in outpatient and inpatient care activities in the United States, Canada, and Australia. The company offers a platform that serves healthcare organizations, including health systems/ integrated delivery networks, academic medical centers, multi-specialty medical groups, single-specialty medical groups, ancillary healthcare organizations, and other outpatient healthcare delivery organizations. Inventurus Knowledge Solutions Limited was incorporated in 2006 and is based in Navi Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
INVENTURUS KNOWLEDGE SO L reported revenue of ₹31.9B in FY2026 versus ₹7.6B in FY2022, a compound +43.0%/yr. Reported net income was ₹7.2B in FY2026, compounding +32.7%/yr from FY2022.
IKS screens 87% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 128 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $282.13 | $91.49 | −68% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | −87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | −64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | −46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | −72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | −69% |
| Waystar Holding WAY | $25.76 | $12.86 | −50% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | −87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | −75% |
Compare INVENTURUS KNOWLEDGE SO L with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is INVENTURUS KNOWLEDGE SO L (IKS) overvalued or undervalued?
What is the fair value of IKS?
What is the quality score of IKS?
What is the revenue of INVENTURUS KNOWLEDGE SO L (IKS)?
What is the net profit margin of IKS?
Does INVENTURUS KNOWLEDGE SO L pay a dividend?
Watch INVENTURUS KNOWLEDGE SO L in the live analysis
One click puts INVENTURUS KNOWLEDGE SO L on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.